Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) ...

Researchers have observed in a new study that stress hyperglycemia (SHR) ratio could be a useful predictor of neovascular ...

Diabetic retinopathy ... PDR: Proliferative DR; RCO: Royal College of Ophthalmologists. NHMRC Dilated ophthalmoscopy or slit-lamp biomicroscopy (dilated) with a lens or photography (non-mydriatic ...